GSTA3 and Hepatic fibrosis: GSTA3 inhibits HSC activation and liver fibrosis by inhibiting MAPK and GSK-3 β signalling pathways, suggesting that GSTA3 could be a feasible target for therapeutic interventions for liver fibrosis (Chen et al., 2019a).